Emerging space for non-polyethene-glycol bowel preparations in inflammatory bowel disease-related colonoscopy: Veering toward better adherence and palatability

Table 1 Summary of studies that examined non-polyethylene glycol-based bowel preparations in patients with inflammatory bowel diseases

Ref.	Bowel preparation	IBD sample size	IBD type, n	Sample age	IBD duration	Disease activity trend	Split regimen as Y/N or %	Clear diet as Y/N or %
Briot et al[14], 2019	MPS, NaP, PicoS	12 (MPS), 26 (NaP), 80 (PicoS)	CD: 8 (MPS), 14 (NaP), 57 (PicoS); UC: 4 (MPS), 11 (NaP), 21 (PicoS); Undetermined IBD: 1 (NaP), 2 (PicoS)	Median: 42.9 (MPS), 41 (NaP), 40.8 (PicoS)	13.9 yr (MPS), 12.9 yr (NaP), 10.6 yr (PicoS)	Remission, mild	58.3% (MPS), 84.6% (NaP), 55.6% (PicoS)	100% (MPS), 100% (NaP), 95.1% (PicoS)
Mohsen et al[17], 2021	PicoS + magnesium citrate + PEG	61	N/A	Mean: 39.7	N/A	Unknown	Y	Y
Rueda García et al[18], 2023	PicoS	31	CD: 18, UC: 12: Undetermined IBD: 1	Mean: 51.7	N/A	Mild	Y	Y
Kim et al[19], 2022	OST	55	CD: 18, UC: 37	Mean: 44.4	93.2 mo	Remission, mild	Y	Y
Lee et al[20], 2023	OSS	92	UC: 92	Mean: 47.9	7 yr	Remission, mild	Y	Y

CD: Crohn's disease; IBD: Inflammatory bowel disease; MPS: Sodium, magnesium, and potassium sulphates; N: No; N/A: Not applicable; NaP: Sodium phosphate; PEG: Polyethylene glycol; PicoS: Sodium picosulphate; OSS: Oral sulphate solution; OST: Oral sulphate tablet; UC: Ulcerative colitis; Y: Yes.